Loading…
Tevogen Inc. is projected to rise to $7.07 by 2027, a +1% move from its current price of $7.02. TVGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $6.53 | $7.02 | $7.55 | +0.06% |
| Aug 6 | $6.34 | $7.03 | $7.79 | +0.12% |
| Aug 7 | $6.20 | $7.03 | $7.98 | +0.18% |
| Aug 8 | $6.09 | $7.04 | $8.14 | +0.24% |
| Aug 9 | $5.99 | $7.04 | $8.28 | +0.30% |
| Aug 10 | $5.90 | $7.05 | $8.42 | +0.36% |
| Aug 11 | $5.82 | $7.05 | $8.54 | +0.42% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.82 | $7.05 | $8.54 | +0.42% |
| Week 2 | $5.39 | $7.08 | $9.29 | +0.84% |
| Week 3 | $5.10 | $7.11 | $9.92 | +1.26% |
| Week 4 | $4.86 | $7.14 | $10.48 | +1.69% |
| Week 5 | $4.66 | $7.17 | $11.02 | +2.11% |
| Week 6 | $4.50 | $7.20 | $11.52 | +2.54% |
| Week 7 | $4.35 | $7.23 | $12.02 | +2.97% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tevogen Bio Holdings Inc. is a clinical-stage healthcare company focused on off-the-shelf, precision T cell therapies for infectious diseases, cancers, and other disorders. Its work centers on TVGN 489, which has completed Phase 1 clinical trial for ambulatory high-risk adult COVID-19 patients, and is in Phase 1 trials to treat acute SARS-CoV-2 infections with B-cell cancer immune suppression and related B-cell–immune-suppressed cases, as well as Long COVID prevention and treatment.
The company is developing several additional product candidates, including TVGN 920 (preclinical for cervical cancer), TVGN 960 (preclinical for oropharyngeal cancer), TVGN 601 (preclinical for multiple sclerosis), TVGN 930 (preclinical for Epstein-Barr virus–associated lymphomas), and TVGN 116 (preclinical for hepatitis B). Tevogen Bio Holdings Inc. was formerly Tevogen Bio Inc.
and changed its name in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey, in the Healthcare sector.
TVGN is currently priced at $6.72 per share with a market capitalization of $28.35M and a rank of 4493 in the market. This places it within the smaller-cap segment of the Healthcare sector.
The near-term price action shows current price alignment with near-term forecasts that include a mixed path through 2026–2029, while the multi-year outlook points to substantial upside into 2030 and beyond. Notably, the 2030, 2040, and 2050 forecasts show meaningful upside: 2030 avg $8.57 with a 27.5% ROI and a bullish sentiment, 2040 avg $15.08 with a 124.4% ROI and bullish sentiment, and 2050 avg $30.84 with a 359% ROI and bullish sentiment.
In the nearer term, the forecast for 2026–2029 presents a range of outcomes with 2026 min $3.89, avg $6.72, max $9.56 (ROI 0) and 2028 min $3.90, avg $5.69, max $9.01 (ROI -15.3%), indicating variability around the current price of TVGN. These figures frame a landscape of potential volatility and eventual longer-term upside.
A major floor 85.9% below — a decisive break under it would weaken the trend.
The nearest floor, 44.6% below — buyers have tended to step in here.
The nearest ceiling, 39.9% above — a clean break opens room to run.
A major ceiling 83.0% above — clearing it would confirm fresh momentum.
Key TVGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TVGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.17 | Buy | $6.22 | Buy |
| MA 10 | $5.20 | Buy | $5.70 | Buy |
| MA 20 | $5.13 | Buy | $5.73 | Buy |
| MA 50 | $7.49 | Sell | $6.71 | Buy |
| MA 100 | $6.97 | Buy | $8.81 | Sell |
| MA 200 | $13.47 | Sell | $16.83 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.24 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 185.80 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.42 | Buy |
| ROC (12) | 47.49 | Buy |
| Bollinger %B (20,2) | 1.07 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -1.79 | Sell |
| Awesome (5,34) | -0.31 | Sell |
| Ultimate (7,14,28) | 83.57 | Sell |
| Momentum (10) | 2.84 | Buy |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 6.96 | Buy |
| ADX (14) | 23.36 | Buy |
| ATR (14) | 0.40 | Info |
The 30-day technical picture leans Neutral, with an RSI of 60. The 50-day simple moving average sits at $7.55, while the 200-day simple moving average is $13.61, suggesting the longer-term trend remains heavier on the upside for larger timeframes but current momentum is modest.
Near-term support is pegged at $3.89 and resistance at $9.82, with the 30-day price range spanning from $4.12 to $10.95. This range highlights the stock’s volatility over the past month and the price levels traders may watch for entries or exits.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.89 | $7.02 | $9.88 | 0% | Neutral | |
| $5.15 | $7.07 | $10.48 | +1% | Neutral | |
| $4.13 | $6.03 | $9.54 | -14% | Neutral | |
| $4.45 | $6.84 | $11.37 | -3% | Neutral | |
| $5.54 | $8.93 | $15.46 | +27% | Bullish | |
| $6.67 | $11.25 | $20.17 | +60% | Bullish | |
| $6.37 | $11.21 | $20.72 | +60% | Bullish | |
| $5.74 | $10.52 | $19.99 | +50% | Bullish | |
| $5.68 | $10.83 | $21.11 | +54% | Bullish | |
| $5.03 | $9.96 | $19.86 | +42% | Bullish | |
| $7.14 | $15.86 | $34.77 | +126% | Bullish | |
| $14.33 | $31.85 | $73.26 | +354% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.89 | $7.02 | $8.50 | +0.00% |
| September 2026 | $6.00 | $7.29 | $9.25 | +3.85% |
| October 2026 | $6.01 | $7.41 | $9.59 | +1.68% |
| November 2026 | $5.74 | $7.16 | $9.42 | -3.41% |
| December 2026 | $5.88 | $7.41 | $9.88 | +3.43% |
Click any year to see its month-by-month TVGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Tevogen Inc.'s 2026 outlook centres on $7.02, within a $3.89 to $9.88 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, TVGN could reach as high as $10.48, with a base case around $7.07 and support toward $5.15 — roughly +1% from $7.02. A consolidation phase looks the most probable path here.
Expect TVGN to range from $4.13 to $9.54 through 2028. The $6.03 average target implies a -14% move from current prices. That is -15% versus the projected 2027 average. Price action looks broadly range-bound.
The TVGN price prediction for 2029 points to an average of $6.84 (low $4.45, high $11.37) — a potential decline of -3% on today's $7.02. A consolidation phase looks the most probable path here.
In 2030, TVGN is projected to trade between $5.54 and $15.46, averaging $8.93 — a potential gain of +27% from today's $7.02. That is up +31% on the projected 2029 average. Momentum favours further upside here.
Tevogen Inc.'s 2031 outlook centres on $11.25, within a $6.67 to $20.17 range. That is up +26% on the projected 2030 average. That marks a +60% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, TVGN could reach as high as $20.72, with a base case around $11.21 and support toward $6.37 — roughly +60% from $7.02. Momentum favours further upside here.
Expect TVGN to range from $5.74 to $19.99 through 2033. The $10.52 average target implies a +50% move from current prices. That is -6% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The TVGN price prediction for 2034 points to an average of $10.83 (low $5.68, high $21.11) — a potential gain of +54% on today's $7.02. Momentum favours further upside here.
In 2035, TVGN is projected to trade between $5.03 and $19.86, averaging $9.96 — a potential gain of +42% from today's $7.02. That is -8% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Tevogen Inc.'s 2040 outlook centres on $15.86, within a $7.14 to $34.77 range. That is up +59% on the projected 2035 average. That marks a +126% change versus current levels. Momentum favours further upside here.
By 2050, TVGN could reach as high as $73.26, with a base case around $31.85 and support toward $14.33 — roughly +354% from $7.02. Buyers look set to stay in control over this stretch.
Investing $1,000 in TVGN today (≈ 142.450142 TVGN) could be worth
$4,537.23
+$3,537.23 (+354%) by 2050 · US Dollar
Based on the average projected TVGN price of $31.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TVGNwould be worth at today's price.
$1,000 invested in TVGN on Jul 31, 2025 (≈ 20.222447 TVGN) would be worth
$141.96
-$858.04 (-85.8%) today · 0.14× · US Dollar
Based on a TVGN entry price of $49.45 vs. today's $7.02.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.49 | $1,563.47 | +56.3% |
| 1 month ago | $5.74 | $1,223 | +22.3% |
| 3 months ago | $6.66 | $1,054.05 | +5.4% |
| 6 months ago | $14.85 | $472.73 | -52.7% |
| 1 year ago | $49.45 | $141.96 | -85.8% |
| All time (4.6y) ago | $496.85 | $14.13 | -98.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TVGN forecast.
Our base-case forecast reaches $14.00 around 2040.
Implied market cap at $14.00: $59.07M
The multi-year forecast paints a bullish trajectory beginning in 2030 and extending through 2050. The 2030 year is forecast at an average of $8.57, with a 27.5% ROI and a bullish sentiment, followed by continued upside through 2031 ($10.69 avg, 59% ROI) and 2032 ($10.80 avg, 60.8% ROI), then into 2033 ($10.03 avg, 49.2% ROI) and 2034 ($10.32 avg, 53.5% ROI), with 2035 ($9.63 avg, 43.3% ROI) also bullish.
The forecast extends to 2040, where the average price is projected at $15.08 with a 124.4% ROI and a bullish sentiment, and to 2050 with an average of $30.84 and a 359% ROI, also bullish. These are estimates, not guarantees, and reflect potential upside over the long term along with substantial volatility (annualized volatility of 100%). Investors should consider the inherent uncertainty and the possibility that actual results diverge from these projections.
Tap a question to reveal the answer.
Avg $8.57, Min $5.31, Max $14.84; ROI 27.5%; Sentiment BULLISH.
Min $3.89, Avg $6.72, Max $9.56; ROI 0; Sentiment NEUTRAL.
Yes—the 2034 forecast max is $20.12 (avg $10.32; ROI 53.5%); sentiment BULLISH.
Avg $15.08, Min $6.78, Max $33.07; ROI 124.4%; Sentiment BULLISH.
Avg $30.84, Min $13.88, Max $70.94; ROI 359%; Sentiment BULLISH.
Tevogen Inc. Community Discussion
0Share your Tevogen Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.